Form D · Pharmaceuticals

Rivus Pharmaceuticals, Inc.

Charlottesville, VA · CIK 0001773293

Offering snapshot reported Jan 16, 2025 · SEC filing

Reported sold
$57M
Offering amount: $57M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 7, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 16, 2025Initial$56,979,133No comparison7SEC filing
Sep 17, 2024Initial$66,000,000No comparison7SEC filing
Sep 17, 2024Initial$65,999,999No comparison7SEC filing
Oct 4, 2021Initial$34,500,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-535494

Source: Form D, filed Jan 16, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Allen Cunningham Director, Executive
Jayson Dallas Director, Executive
Francesco De Rubertis Director
Derek Di Rocco Director
Patrick Enright Director
Nancy Hargreaves Executive
Shaharyar Khan Director, Executive
Erin Lavelle Director
Tom O'neil Executive
Robert Schott Executive
Ian Smith Director
Rick Winningham Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
501 Locust Avenue, Suite 301
Charlottesville, VA, 22902